U Alberta Rheumatology study of GCAPS score in 62 new onset, suspected GCA referrals. GCA Dx in 39 pts excluded in 23. 50% had a High risk GCAPS (screening) score, 38% Intermediate & 13% had Low risk GCAPs. Intermediate or High risk GCAPS sensitivity 97%, specificity 30%, PPV 70% https://t.co/gKD1Je3QRH

True or False: In a 6-month RCT for refractory ITP, combining baricitinib with danazol achieved a durable response rate more than double that of danazol monotherapy. Take this week's RheumIQ quiz at https://t.co/yQn8cIT5Cw to see if you got it right! https://t.co/MJSw1gYUob

• RheumIQ Weekly Quiz | RheumNow

New Avacopan Analysis Sent to FDA After data manipulation allegations, the FDA has been calling for the vasculitis drug to be pulled from the market since January. Amgen has submitted a third-party review of avacopan's (Tavneos) pivotal trial data and other analyses to the FDA https://t.co/zBg4pFBfSP

Top 20 Best Rheumatology Hospitals U.S. News & World Report has published its Best Hospitals for 2026-2027, listing the best among many specialties, including rheumatology. At the top of the list are Johns Hopkins Hospital, Cleveland Clinic, Hospital for Special Surgery (HSS), https://t.co/IjGwcDQehq

A Tribute to Daniel L. Kastner, MD, PhD (1951–2026) The rheumatology, genetics and NIH communities mourn for Dr. Daniel L. Kastner, who died on July 28, 2026, in Bethesda, Maryland, at age 74. https://t.co/Qti4Nay6NX https://t.co/gjmY7G4XAc

• A Tribute to Daniel L. Kastner, MD, PhD (1951–2026) | RheumNow

JAMA Review of Hip Fracture The July 16th edition of JAMA reviews the highly prevalent problem of hip fractures - a major global health burden: 14.2 million occur worldwide annually (280,000 in the US), with global incidence higher in women (833.9/100,000) than men https://t.co/KBUovkYPB1

Cassi Calabrese @CCalabreseDO easy overview of vaccinating IMID pts. Vaccinating IMID pts. Stresses risk-based approach: RZV for all JAK-i/anifrolumab pts regardless of age; time COVID vax around rituximab; annual flu + PCV20/21 for all immunosuppressed; RSV ≥75 or younger w/ https://t.co/AHykuqJn2N

Best proof of difference betw Seropos vs seroneg RA from TREAT-EARLIER 12 mos study 236 clinically suspect arthralgia pts w/ subclinical Jt inflammation Rx w/ MTX vs PBO. MTX prevented RA only the seroneg RA (9 v 35%); But no protection in seropos RA (58 vs 65%) https://t.co/A5aFUgMPQR

Four Decades of Gout Management During this month-long campaign on Gout, we have documented many significant changes in our approach to gout, as well as many unmet needs and deficiencies that merit our continued primary attention. https://t.co/ddzj3RktDD https://t.co/x7o0HfWqHa

• Four Decades of Gout Management | RheumNow

JAMA Review of Hip Fracture The July 16th edition of JAMA reviews the highly prevalent problem of hip fractures - a major global health burden: 14.2 million occur worldwide annually (280,000 in the US), with global incidence higher in women (833.9/100,000) than men https://t.co/TiiCjoq2Hj

New, Advanced Therapies in Gout New, Advanced Therapies in Gout explores the rapidly evolving therapeutic landscape beyond conventional urate-lowering therapy. https://t.co/0uNK0nOEp6 https://t.co/YD7tQu2QrT

• New, Advanced Therapies in Gout | RheumNow